Join our daily newsletter At The Bell to receive exclusive market insights
- Patrys (PAB) releases pre-clinical data for an animal study of its lead PAT-DX1 product showing the product improves the efficacy of radiation therapy
- Treatment with the drug showed “significantly prolonged” survival in rats with high-grade glioma (HGG), an aggressive form of brain cancer, compared to radiation alone
- Patrys says even at a lower dose than previously used, PAT-DX1 shows significant activity as a single agent, confirming previous studies in a range of brain cancer models
- The company says the results offer the potential for future clinical strategies that allow the reduction of radiation doses and its associated side effects, particularly in children
- Shares in Patrys are up 12.5 per cent and trading at 2.7 cents as of 1:50 pm AEST
Patrys (PAB) has released pre-clinical data for an animal study of its lead PAT-DX1 product showing the product improves the efficacy of radiation therapy.
Specifically, Patrys said PAT-DX1 resulted in “significantly prolonged” survival in rats with high-grade glioma (HGG), an aggressive form of brain cancer, compared to radiation alone.
The study was conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre and showed combining a therapeutic dose of standard radiation therapy with a 25-milligrams-per-kilogram dose of PAT-DX1 increased the median survival in subjects by 12 days compared to just radiation treatment.
Additionally, even at a lower dose than previously used, PAT-DX1 showed significant activity as a single agent, confirming previous studies in a range of brain cancer models.
Patrys CEO and Managing Director James Campbell said the study showed a robust benefit from combining PAT-DX1 with standard-of-care radiation therapy in one of the most difficult-to-treat cancers.
“This, and additional studies funded under the auspices of Cure Brain Foundations’ Clinical Accelerator program, of which our collaborator Professor Johns was the inaugural recipient, will guide us towards optimised therapeutic regimes and timing schedules as we progress PAT-DX1 into the clinic,” Dr Campbell said.
“Having successfully completed our engineering run for PAT-DX1 recently, we are well positioned to advance towards the clinic and excited by the potential of this novel and exciting agent.”
Professor Johns added that the “impressive” results offered the potential for future clinical strategies that allowed the reduction of radiation dose and its associated side effects, particularly in children.
Shares in Patrys were up 12.5 per cent and trading at 2.7 cents as of 1:50 pm AEST.
